Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four normal thyroids and 51 papillary carcinomas (PCs) were generated using DNA microarrays. The tumors were genotyped for their common activating mutations: BRAF V600E point mutation, RET/PTC1 and 3 rearrangement and point mutations of KRAS, HRAS and NRAS. Principal component analysis based on the entire expression data set separated the PCs into three groups that were found to reflect tumor morphology and mutational status. By combining expression profiles with mutational status, we defined distinct expression profiles for the BRAF, RET/PTC and RAS mutation groups. Using small numbers of genes, a simple classifier was able to classify correctly the mutational status of all 40 tumors with known mutations. One tumor without a detectable mutation was predicted by the classifier to have a RET/PTC rearrangement and was shown to contain one by fluorescence in situ hybridization analysis. Among the mutation-specific expression signatures were genes whose differential expression was a direct consequence of the mutation, as well as genes involved in a variety of biological processes including immune response and signal transduction. Expression of one mutationspecific differentially expressed gene, TPO, was validated at the protein level using immunohistochemistry and tissue arrays containing an independent set of tumors. The results demonstrate that mutational status is the primary determinant of gene expression variation within these tumors, a finding that may have clinical and diagnostic significance and predicts success for therapies designed to prevent the consequences of these mutations.
Thyroid cancer poses a significant clinical challenge, and our understanding of its pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid carcinoma, transcriptional profiles of four normal thyroids and 51 papillary carcinomas (PCs) were generated using DNA microarrays. The tumors were genotyped for their common activating mutations: BRAF V600E point mutation, RET/PTC1 and 3 rearrangement and point mutations of KRAS, HRAS and NRAS. Principal component analysis based on the entire expression data set separated the PCs into three groups that were found to reflect tumor morphology and mutational status. By combining expression profiles with mutational status, we defined distinct expression profiles for the BRAF, RET/PTC and RAS mutation groups. Using small numbers of genes, a simple classifier was able to classify correctly the mutational status of all 40 tumors with known mutations. One tumor without a detectable mutation was predicted by the classifier to have a RET/PTC rearrangement and was shown to contain one by fluorescence in situ hybridization analysis. Among the mutation-specific expression signatures were genes whose differential expression was a direct consequence of the mutation, as well as genes involved in a variety of biological processes including immune response and signal transduction. Expression of one mutationspecific differentially expressed gene, TPO, was validated at the protein level using immunohistochemistry and tissue arrays containing an independent set of tumors. The results demonstrate that mutational status is the primary determinant of gene expression variation within these tumors, a finding that may have clinical and diagnostic significance and predicts success for therapies designed to prevent the consequences of these mutations.
Introduction
Papillary carcinoma (PC) is the most common type of thyroid cancer, representing up to 80% of all malignant thyroid tumors (Hundahl et al., 1998) . The majority of PCs are not life threatening and are effectively treated with thyroidectomy followed by radioactive iodine ablation (DeGroot et al., 1990) . However, a minority of PCs recur and cause significant morbidity (LiVolsi, 1996; Hundahl et al., 1998) . Furthermore, an even smaller minority of PCs undergo progression from welldifferentiated carcinoma to either poorly or undifferentiated carcinoma, an event associated with marked reduction in survival (Giuffrida and Gharib, 2000) .
The etiology of PC is incompletely understood despite recent advancements (for reviews, see Moretti et al., 2000; Fagin, 2002; Bongarzone and Pierotti, 2003; Segev et al., 2003) . Activating mutations of several genes in the RET/RAS/BRAF/MAPK signal transduction pathway have been identified in the majority of PCs. Specifically, mutations have been identified in the RAS gene family (Suarez et al., 1988; Bongarzone et al., 1989; Namba et al., 1990; Karga et al., 1991; Capella et al., 1996; Ezzat et al., 1996) and in one member of the RAF kinase family, BRAF Kimura et al., 2003; Nikiforova et al., 2003; Soares et al., 2003) . Furthermore, PCs contain the well-characterized RET/PTC rearrangements with variable frequency (Santoro et al., 1992) , in part dependent on geographic factors and radiation exposure (Bounacer et al., 1997; Rabes et al., 2000) . Interestingly, these three mutation groups appear to be mutually exclusive Soares et al., 2003) and are thought to be functionally similar . These mutations are believed to be among the earliest initiating mutations in PC, and are followed by additional mutations, that is, loss of tumor suppressor genes such as TP53 (Donghi et al., 1993; Dobashi et al., 1994) and PTEN (Frisk et al., 2002) , that correspond to and facilitate the progression towards poorly differentiated and undifferentiated carcinoma.
Molecular profiling demonstrates tremendous potential to elucidate various aspects of carcinogenesis. Genomic and proteomic molecular profiling is providing new insights into cancer by revealing distinctive gene expression patterns associated with a wide variety of molecular and clinical parameters (Hanash, 2004) . These approaches are beginning to be applied to thyroid cancer (Huang et al., 2001; Barden et al., 2003; Aldred et al., 2004; Chevillard et al., 2004; Finley et al., 2004; Frattini et al., 2004; Hawthorn et al., 2004; Mazzanti et al., 2004; Wreesmann et al., 2004) and should yield significant improvements in thyroid cancer diagnosis, prognosis and treatment.
In this study, we combined transcriptional expression profiles of 51 PCs with their morphology and RET/ PTC, BRAF and RAS mutational status, and thereby demonstrated relationships between gene expression and morphology, and gene expression and mutation. These results refine the classification of PC and improve our understanding of its pathobiology.
Results
Mutational analysis for BRAF, RAS family genes and RET/PTC1 and 3 rearrangements To uncover relationships between gene expression and activating mutations of the RET/RAS/BRAF/MEK/ ERK pathway within PC, the mutational status of RAS, RET/PTC and BRAF for all but one of the PCs was determined. RET/PTC translocation status was determined for the two most common translocations, RET/ PTC1 and RET/PTC3. The BRAF mutational analysis was restricted to its most common mutation in adult sporadic PCs, BRAF
T1799A
. Point mutations within the RAS gene family were determined by examining codons 12 and 13 for KRAS and codon 61 of NRAS and HRAS.
The results are detailed in Table 1 . Among the entire cohort of 51 PCs, 38 were derived from UMHS, four from CHTN and nine from UC. Eight of the nine samples derived from UC were specifically included to enrich the data for RET/PTC mutant PCs, and are thus excluded from the following mutation frequency calculations. The relative frequency for the three mutations among the remaining unselected PCs (two tumors were not RAS genotyped and one additional tumor was not genotyped for RET/PTC or BRAF) was as follows: BRAF 25/41 (61.0%), RET/PTC 1/41 (2.4%) and RAS 5/40 (12.5%). Collectively, BRAF, RET/PTC or RAS mutations were identified in 31/42 (73.8%) PCs. There was no overlap between mutations, as each tumor demonstrated no more than one mutation. These mutation frequencies are consistent with other published studies (Nikiforov, 2002; Kimura et al., 2003) .
Gene expression profiles identify three groups of PCs that reflect morphology and mutation
We used principal components analysis (PCA) to carry out an unsupervised examination of the relationship between tumor morphology and global gene expression in the PCs. As seen in Figure 1a , a relationship between morphologic subtype of PC and gene expression was clearly observed. The follicular variants (FV) were tightly grouped in the PCA plot, and the tall cell (TC) variants were loosely grouped among the remaining classic types (CT). This relationship between morphology and gene expression profile is consistent with other studies of endocrine tumors (Giordano et al., 2003) , and can be interpreted as evidence for the biological relevance of the expression profiles. We also used PCA to examine the relationship between mutation type and gene expression in the PCs. Incorporating the BRAF, RET/PTC and RAS mutational status into the PCA plot revealed a strong relationship between mutation and gene expression (Figure 1b) , with PCs with each mutation type closely grouped. Interestingly, tumors with BRAF mutations displayed either TC or CT morphology, tumors with RET/PTC rearrangements displayed predominantly the CT morphology and tumors with RAS mutations exclusively displayed the FV morphology. Tumors with no apparent mutation predominantly had the FV morphology. Some of 10 tumors without BRAF, RET/PTC or RAS mutation (Figure 1a and b) revealed that mutation was more strongly correlated with gene expression than morphology. Thus, while morphology and mutation were both related to gene expression, mutational status was a better explanation of the variation in gene expression between samples than tumor morphology.
Transcriptional signatures associated with BRAF, RET/PTC and RAS mutations
To identify differentially expressed genes among the three mutational PC groups, we fit a one-way ANOVA model to the log-transformed data for the three groups of samples and computed tests for differences between every pair of groups. We also computed fold-changes for each probe-set for every pair of groups by taking the antilogarithm of the differences in the means of the logtransformed data. In order to estimate the false discovery rates (FDRs), identical calculations were performed on 1000 additional data sets for which the sample labels were randomly permuted. We obtained 3690 and 3537 probe-sets with Po0.01 when comparing RET/PTC mutants and BRAF mutants to RAS mutants, respectively, and 3891 probe-sets with Po0.01 for BRAF vs RET/PTC mutant samples, this being approximately 20 times as many as obtained for the permuted data sets on average. We reduced the number of differences to consider by selecting for those that yielded Po0.01 as well as a fold-change greater than 2 (or less than 0.5) for any group compared to each of the other two groups. This resulted in 132 probe-sets for RET/PTC mutants (100 up, 32 down, FDR ¼ 1.1%), 82 probe-sets for BRAF mutants (31 up, 51 down, FDR ¼ 0.5%) and 571 probe-set for the RAS mutant group (165 up, 406 down, FDR ¼ 1.4%). Note that the 406 probe-sets selected as being reduced in the RAS mutant group are probe-sets that are larger in the two other mutant groups, indicating that many increases in gene expression are common between BRAF and RET/ PTC mutant tumors. The data set, with indications of the probe-sets obtained by the various selection criteria above, as well as others, are publicly available as a supplement at http://dot.ped.med.umich.edu:2000/ pub/pap_thyroid/index.htm. We present subsets of 20 distinct genes with the smallest P-values for the probesets selected as up or down in each of the three mutation groups in Figure 2 .
Among the differentially expressed genes shown in Figure 2 are genes whose increased expression is the direct consequence of the mutation, that is, increase RET expression in PCs with RET/PTC rearrangements, as well as genes involved in a variety of biological processes, including immune response and signal transduction. For example, the most differentially expressed gene in the BRAF mutants is TM7SF4, which encodes a dendritic cell protein and is likely related to immune response in these tumors.
Accurate prediction of PC mutational status using marker genes
We then considered the possibility that gene expression profiles of a few marker genes could predict the mutational status of the PCs. Given the unavailability of an independent testing expression data set, a leaveone-out crossvalidation approach (see Materials and methods) was used to test the classifier. This method is a robust and acceptable alternative statistical approach when separate training and testing sets are not available (Stone, 1977; Beer et al., 2002) . Using the 40 PCs with identified mutations, we performed leave-one-out crossvalidation based on the best G genes increased in each mutant group, as a way of estimating the misclassification rates expected when presented with new samples.
We left out each PC once and used the other 39 to select G genes increased in each group in a manner that would select genes in the order given in Figure 2 , except that excluding a sample alters the selection, as detailed in Materials and methods. Using G ¼ 1, 2, y, 10 always gave correct classification for each left out PC, with one exception. THY105, a BRAF mutant, was classified as a RET/PTC mutant when only two probe-sets per group were selected. This tumor expressed considerable RET and may be a PC with more than one type of activating mutation.
Given the excellent accuracy of the classifier when using PCs with known mutations, we then analysed the PCs without apparent mutations using a similar approach. Using the G ¼ 1, 2, y, 30 gene per group classifier trained on all 40 PC samples, we classified the 11 remaining PCs without know mutations and the results are detailed in Table 2 . THY006 (the rightmost sample in Figure 2 ), the mutational status of which was not determined, was uniformly classified as a BRAF mutant and had the CT morphology consistent with that predicted genotype (not shown). THY152 was always classified as a RET/PTC mutant regardless of the number of genes used by the classifier. Flourescence in situ hybridization (FISH) later demonstrated that this PC contained a RET/PTC rearrangement, illustrating the accuracy of the classifier (see below). Four PCs (THY048, THY049, THY140 and THY185) had FV morphology and were classified exclusively as RAS mutants. Another FV, THY164, was classified as a RAS mutant when G>3 and a BRAF mutant when Go4. THY004 was classified as a RAS mutant for all numbers of genes per class, except when 15 genes were used. The remaining three tumors (THY073, THY098 and THY149) were variably classified depending on the number of genes per class (see Table 2 ). The mutational analysis of these tumors will be investigated in a future study; specifically, the tumors will be examined for other, rarer RAS mutations, that is, HRAS codons 12/ 13, NRAS codons 12/13 and KRAS codon 61, for other RET rearrangements, and for BRAF mutations other than T1799A.
Testing the accuracy of the mutational classifier by FISH evaluation of a misclassified PC THY152, one of the PCs with no apparent mutation, was studied to test the accuracy of the mutation classifier. This case was located in the PCA plot away from the other PCs with no mutations (Figure 1b,  arrow) , and the mutational classifier uniformly predicted it contained a RET/PTC rearrangement (see above). Additional PCR-based testing of THY152 confirmed the absence of RET/PTC1 and RET/PTC3 translocations. FISH technology was used since it has virtually absolute resolution in determining the presence of any type of RET gene rearrangement. A fluorescently labeled probe spanning the entire RET gene was used so that rearrangement would result in a split of one of two RET signals. The analysis revealed such a split in most of the tumor cells (Figure 3a) . Two-color hybridization Figure 2 Gene expression profiles of 50 PC with BRAF, RET/ PTC, RAS or no apparent mutation (THY006 is not included). Differentially expressed genes were identified using a one-way ANOVA comparing BRAF vs RET/PTC vs RAS mutants as described in Results. The 20 genes shown in each category are those for which fold-changes were at least 2 compared to the other two groups, and for which the larger of the two P-values obtained when comparing one group to the other two groups was minimal (with most significant genes at the top for each category). Repeated probe-sets for the same gene have been removed. The order of the 11 samples for which no mutations were detected is as given in Table 2 Molecular profiles of papillary carcinoma TJ Giordano et al with the RET and either H4 (RET/PTC1 partner) (Figure 3b ) or ELE1 (RET/PTC3 partner) (not shown) probes revealed two copies of H4 and ELE1, and no juxtaposition between any of them and RET, indicating the presence of a RET rearrangement, which is different from these two most common types.
Testing the BRAF mutation gene expression signature using thyroid peroxidase (TPO) immunohistochemistry (IHC) in PC tissue arrays TPO expression is decreased at the transcriptional level in PC (Smanik et al., 1994; Tanaka et al., 1996) . Our gene expression data concurs with TPO decreased in the 51 PCs compared to normal thyroid (NT) controls by an average of 18.9-fold (P ¼ 0.0007 by two-sided t-test). However, in our data set, TPO was not significantly decreased in RAS mutant PCs compared to NTs since two of the five RAS mutant tumors gave values as large as the NTs. More importantly, in our data, BRAF mutant PCs gave the lowest TPO expression values on average, and these were significantly lower than in RAS (P ¼ 0.0005, 8.7-fold lower) or RET/PTC mutant PCs (P ¼ 0.0009, 5.12-fold lower). TPO gave the largest fold decrease in BRAF compared to RAS and RET/PTC tumors of any gene measured on our arrays, but was 22nd best as measured by the maximum of these two P-values, and therefore does not appear in Figure 2 , which gives only the best 20 genes by this measure. Each of the three groups of mutant PCs had greater than 10-fold ranges for the expression values of TPO and a range of more than 100-fold when combined. Although it was not the best RNA measured in terms of discriminating mutant classes, because of the large differences between samples and groups of samples in expression levels of TPO, we then asked if corresponding protein assays could be used to detect such differences. We used IHC to examine TPO protein expression in an independent set of primary and metastatic PCs present in two tissue arrays in which the BRAF mutation status was determined. A four-point visual interpretation of TPO immunoreactivity resulted in a correlation between TPO protein and BRAF mutational status ( Figure 4A ). Representative examples of TPO IHC with BRAF mutational annotation are shown in Figure 4B .
Discussion
Molecular profiling has rapidly become an effective approach to further understanding of the pathogenesis of numerous cancer types (Balmain et al., 2003; Ciro et al., 2003; Luo et al., 2003; Hanash, 2004) . Here, we profiled gene expression at the RNA level in a large cohort of PCs with the ultimate goal being to refine the classification of PC and improve understanding of its biology. By combining expression profiles with morphologic phenotype and genotype, strong relationships between gene expression and morphology, and gene expression and BRAF, RAS and RET/PTC mutation were uncovered. Furthermore, we identified hundreds of differentially expressed genes between the three mutational classes of PCs with estimated FDRs of only about 1%, and have shown that using even very small subsets of genes, it was possible to predict the mutational class of a tumor almost without error.
The finding that gene expression in a tumor reflects its morphology is not unexpected and is consistent with the literature on a variety of tumor types (Schwartz et al., 2002) , including other endocrine organs (Giordano et al., 2003) . However, correlation between gene expression and mutation has not been observed in many solid tumor types, with the exception of tumors with dominant activating mutations, such as sarcomas with KIT mutations (Allander et al., 2001) or characteristic translocations (Schaefer et al., 2004) , melanomas with BRAF mutations (Pavey et al., 2004) , hereditary breast TC  FV  FV  FV  FV  FV  FV  CT  FV  FV  CT  # of genes per class THY004  THY048 THY049 THY073  THY098  THY140 THY149  THY152  THY164 THY185 Genes used by the classifier were selected by the other 40 tumors with known mutations from a set of 15 266 probe-sets that were not redundant for the genes (assessed via unigene IDs). For each of the 11 PCs, the predicted mutation based on the number of genes used by the classifier is shown, as well as the morphologic type of each tumor (Hedenfalk et al., 2001 ) and ovarian carcinoma (Jazaeri et al., 2002) , and breast carcinomas that overexpress ERBB2 (Bertucci et al., 2004) or have mutated TP53 (Sorlie et al., 2001) . A KRAS2 expression signature of lung adenocarcinomas, not apparent from human tumors alone, was recently derived by combining expression profiles of human and mouse tumors (Sweet-Cordero et al., 2005) . Our molecular profiling and genotyping studies support the currently held dogma that constitutive activation of one of the components of the RET/RAS/ BRAF/MAPK pathway is an event common to all PCs. The striking relationship between gene expression and genotype indicates that mutations affecting this pathway are the predominant source of gene expression variation and suggests that they represent the earliest mutational events occurring in PC, resulting in persistent and distinct patterns of abnormal gene expression. This is supported by findings of RET/PTC rearrangements in papillary microcarcinomas, that is, PCs of less than 1 cm in size (Viglietto et al., 1995) . In addition, the absence of a spectrum of dysplasia in well-differentiated PC, in contrast to other epithelial tumor types such as colon carcinoma, suggests that PCs are the morphologic manifestation of single dominant activating mutations. Interestingly, borderline serous tumors of the ovary share morphologic and molecular features with PC, as each have papillary architectures and a high frequency of BRAF and RAS mutations (Singer et al., 2003) . Consistent with the PC model, BRAF and RAS mutations are believed to be early events in the development of these tumors (Ho et al., 2004) . However, our data does not preclude the possibility that other mutations that tightly segregate with BRAF, RET/PTC or RAS mutations are present in PC.
In contrast to our study, in which we found that even unsupervised methods distinguish between mutants types, a similar though smaller profiling study showed no strong differences in global gene expression (Frattini et al., 2004) , but did report some expression differences between tumors with RET or NTRK1 rearrangement and tumors with BRAF mutation. They suggested that the mutations identified in their Italian cohort are functionally equivalent with regard to signaling and represent a homogeneous group. These results are unexpected, considering their cohort included 14 PCs with TC morphology, a group believed to be biologically distinct from ordinary or classical PCs (Prendiville et al., 2000; Machens et al., 2004) . Possible sources for the discrepancy between these studies include RNA quality, sample size, different DNA microarray platforms, and genetic or environmental differences (e.g. dietary iodine) in the Italian patients compared with the United States patients studied here.
One of the most interesting aspects of this work is our ability to define mutation-specific gene expression profiles for the RET/PTC, RAS and BRAF oncogenes, which encode effectors residing along the linear MAPK signaling pathway. This finding suggests that these mutations are able to signal through alternative pathways, and may confer tumors with discrete mutationspecific phenotypical and biological features. Evidence in support of these possibilities is emerging. First, PCs with BRAF mutations have been reported to follow a more aggressive clinical course Begum et al., 2004) . Second, PCs with the follicular architecture tend to have RAS mutations (De Micco, 2003; Zhu et al., 2003) , a finding confirmed by this study. Finally, recent cell culture experiments demonstrated that RET/PTC3 mutants signaled preferentially through phosphoinositide 3-kinase (PI3K) compared to MAPK (Miyagi et al., 2004) . In addition, several of the mutation-specific differentially expressed genes in PC have roles in signal transduction such as VAV3, ERBB3, MET, DAPP1 and DUSP6. VAV3 is a member of the VAV oncogene family and is involved in PI3K signaling and subsequent akt activation. Its preferential expression in the PCs with RET/PTC and RAS mutations is a provocative finding that is consistent with the RET/ PTC3 cell line data and may provide additional evidence that these PCs signal more through PI3K than MAPK pathways.
Several of the mutation-specific differentially expressed genes are known to be altered in thyroid tumors. Much work has been carried out on the MET oncogene, which has been shown to be expressed in PC, especially the TC variant of PC (Nardone et al., 2003) , and is thought to have a role in its pathogenesis (Ruco et al., 2001) . Our data confirm increased MET expression in PC, and suggests its expression may be mutationspecific. TIMP1, which is also known to be expressed in PC (Huang et al., 2001; Wasenius et al., 2003; Hawthorn et al., 2004) , may also be preferentially expressed in a mutation-specific manner.
Several of the mutation-specific differentially expressed genes are known to participate in the regulation of the immune response including TM7SF4 (also DCSTAMP), CLECSF2, STAT1 and LY75. The identification of TM7SF4 as the one of the most preferentially expressed genes in the PCs with BRAF mutations has implications for the immunologic aspects of PC. TM7SF4 is a transmembrane protein expressed in dendritic cells and has a role in antigen processing and initiation of the immune response. Its expression profile suggests that BRAF mutation has a unique role in initiating an immune response in PC (Baker, 1995; Juhasz and Farid, 1996; Batistatou et al., 2002) .
Over the last few years, it has been increasingly clear that cancers can be broadly divided into two categories related to their genotype: those with dominant activating mutations in a relatively stable genomic background and those with multiple activating and loss of tumor suppressor gene mutations in a complex genetic background. Tumors with dominant activating mutations include many of the leukemias and lymphomas, as well as many of the sarcomas. Tumors with complex mutational spectra include most of the common epithelial tumors such as lung and colon carcinoma. The relationship between gene expression and mutation in this study suggests that PC fits better within the genetically simple group. It is also interesting to note that balanced translocations occur in some well-differentiated thyroid carcinomas, similar to the situation in hematopoietic malignancies and sarcomas. This observation has therapeutic implications, as tumors with dominant activating mutations are proving to be more susceptible to targeted molecular therapies (Dancey, 2004; Lynch et al., 2004; Paez et al., 2004) .
The delineation of mutation-specific gene expression signatures of PC will become diagnostically significant as the genotyping of PC becomes integral to therapeutic decisions. This scenario is likely to occur in the coming years as newer molecularly targeted therapies become available (see below). Despite the ability to predict mutation status by morphology (e.g. RAS mutation in FVPC), and the fact that it is technically straightforward to identify mutations directly in PCs via molecular diagnostics, there may still be a role for surrogate markers of specific mutations that can be implemented using widely available immunohistochemical approaches.
The finding and validation of reduced TPO expression in BRAF mutant PCs may have clinical significance. As TPO plays a vital role in the synthesis of thyroid hormone, our results suggest that BRAF mutant tumors would display less radioiodine uptake, and thus be less responsive to radioiodine therapy. If true, these observations may be related to the observation that BRAF mutant tumors are associated with a worse prognosis Begum et al., 2004) .
Kinase inhibitors, such as imatinib mesylate (Gleevec), have been shown to be effective in a variety of tumor types and are rapidly becoming accepted as cancer therapeutics (Sawyers, 2003) . BAY 43-9006 is a novel investigational cancer therapeutic that potently inhibits the serine/threonine kinases RAF-1 and wildtype and V600E mutant BRAF, as well as several receptor tyrosine kinases (Lyons et al., 2001; Lowinger et al., 2002; Karasarides et al., 2004; Wilhelm et al., 2004) . Similarly, studies of several small molecule RET inhibitors such as RPI-1 (Cuccuru et al., 2004) , PP2 (Carlomagno et al., 2003) and ZD6474 (Carlomagno et al., 2002) suggest that RET oncoproteins are valid therapeutic targets. One of the most important aspects of the work presented here is the implication that RAF and RET inhibitors will be effective in PCs with BRAF and RET/PTC mutations, respectively. Recent evidence that PCs with RET/PTC3 translocations signal preferentially through the PI3K signaling pathway, rather than the RAS/RAF/MEK/ERK pathway (see above), predicts that there may be differences in therapeutic response based on their underlying mutational status. However, there is much to learn regarding predicting response to therapy in general, and these compounds should be evaluated in PCs with the full mutational spectrum. On the other hand, should there be differential responses to inhibitors dependent on mutation, the functional classification of PC will be modified to incorporate their mutational status.
In summary, we report here that transcriptional profiles of 51 PCs generated using oligonucleotide DNA microarrays allowed us to define three main groups of PC that closely correlate with the presence of BRAF, RET/PTC and RAS mutations, and also with tumor morphology. These findings indicate that mutational status is the principal determinant of gene expression variation within these tumors, predicting success for therapies designed to block the consequences of these specific mutations.
Materials and methods

Tumors, histopathology and RNA isolation
The majority of tissues used in this study were procured from surgical pathology specimens from the University of Michigan (UM) via the Tissue Procurement Service (TPS). Additional selected tissues were procured from the University of Cincinnati Medical Center (UC) and the Cooperative Human Tissue Network (CHTN). IRB approval was obtained. The 55 thyroid tissues used in this study included four NT samples and 51 PCs. All PCs were diagnosed using accepted criteria . To confirm the diagnoses and ensure research tissues were consistent with the final pathologic diagnosis, frozen section slides were reviewed, as were the original permanent sections, when available. Features of the 51 PCs used in this study are shown in Table 1 . The morphology of each PC is shown in Supplementary Figure 1 (see Supplemental information) to document the diagnosis of PC, given the interobserver variability known to exist in its diagnosis . The PCs from UMHS were unselected, except that tumors had to be large enough to have surplus tissue for procurement. Eight of the nine PCs from UC were selected a priori for their known RET/PTC rearrangements to enrich the study for these tumors.
All tissues and RNAs were processed and extracted similarly. Tissues were embedded in OCT embedding medium (Tissue-Tek, Sakura Finetek, Torrence, CA, USA), frozen in liquid nitrogen and stored at À801C. H&E-stained frozen sections were examined to select a representative area of tumor for RNA extraction. Single 2-3 mm 3 tissue isolates were removed from the selected area of the block and immediately homogenized in the presence of Trizol reagent (Life Technologies, Gaithersburg, MD, USA) to prepare total RNA according to the manufacturer's procedures. RNA samples were further purified using acid phenol extraction and RNeasy spin columns (Qiagen, Valencia, CA, USA) and used to prepare cRNA probes. RNA quality was assessed by 1% agarose gel electrophoresis in the presence of ethidium bromide. RNA samples that did not show intact 18S and 28S ribosomal bands were excluded. To acquire profiles of the 55 thyroid samples, RNA was extracted from 78 thyroid samples.
Oligonucleotide microarray analysis
This study used commercially available oligonucleotide DNA microarrays (U133A GeneChip, Affymetrix, Santa Clara, CA, USA). Preparation of cRNA, hybridization, scanning and image analysis of the arrays were performed according to the manufacturer's protocols and as described previously (Giordano et al., 2001) . The U133A arrays consist of 22 283 probesets with 68 control probe-sets, each representing a transcript. Each probe-set typically consists of 11 perfectly complementary 25 base-long probes (PMs), as well as 11 mismatch probes (MMs) that are identical, except for an altered central base. A representative PC (THY074) was selected as the standard and probe-pairs for which the standard had PM-MM oÀ100 (15 631 probe-pairs) were excluded from further analysis. Trimmed-means for each probe-set on each chip were computed as the average of the PM-MMs for a probe-set after discarding the largest and smallest 20% of the PM-MM differences. The standard was scaled to give average trimmedmean of 1500 U. A quantile normalization procedure was used to adjust for differences in the probe intensity distribution across different chips. We applied a monotone linear spline to each chip that mapped quantiles 0.01 up to 0.99 (in increments of 0.01) exactly to the corresponding quantiles of the standard. Next, the data from each chip were log transformed using the log transform y ¼ log(max(x þ 50,0) þ 50). The data set, raw .CEL files, additional Supplemental information and the code to perform these computations are available at http:// dot.ped.med.umich.edu:2000/pub/pap_thyroid/index.htm.
Genotyping of PC
The PCs were genotyped for their common activating mutations, that is, RET/PTC1 and RET/PTC3, V600E BRAF, and HRAS, NRAS and KRAS, as described below. THY006 was only genotyped for RAS, and THY004 and THY164 were only genotyped for BRAF and RET/PTC.
Detection of BRAF mutations Detection of V600E BRAF mutation was performed using real-time PCR and fluorescence melting curve analysis (FMCA) from DNA as reported previously , or from cDNA using primers 5 0 -CGACAGACTGCACAGG-3 0 and 5 0 -TGACTTC TGGTGCCAT-3 0 and the same probes.
Detection of RET/PTC rearrangements Two major types of the rearrangement, RET/PTC1 and RET/PTC3, were detected from RNA by RT-PCR with primers flanking the respective fusion point, followed by agarose gel electrophoresis of the PCR products as reported previously (Nikiforova et al., 2002) .
Detection of RAS mutations Point mutations of the RAS gene most commonly found in thyroid cancer, NRAS codon 61, HRAS codon 61 and KRAS codons 12/13, were detected from DNA using PCR and FMCA on LightCycler as reported previously . spanning the entire RET gene was labeled with SpectrumReddUTP (Vysis, Abbott Park, IL, USA) and used as a probe. A BAC clone RP11-481A12 was used as a probe for ELE1, and a contig of two BAC clones (RP11-43543 and RP11-369L1) as a probe for H4. The ELE1 and H4 probes were directly labeled with SpectrumGreen-dUTP using a nick translation kit (Vysis, Abbott Park, IL, USA). Hybridization was performed on tumor touch preparations obtained from snap-frozen tissue and fixed in 3 : 1 methanol/acetic acid as described previously (Ciampi et al., 2005) . Microscopy was performed with a Leica TCS 4D confocal laser scanning fluorescence microscope with digital image capture.
Mutation classifier
Software was written to perform leave-one-out crossvalidation of a classification scheme that classifies a sample into one of the three possible mutational classes analysed here. The classifiers use the 40 PCs with known mutations and G genes per group, where we studied the cases G ¼ 1,2, y, 30, as detailed in Table 2 . Each sample was left out in turn, and the remaining 39 samples analysed using a one-way ANOVA model on log-transformed data, which results in P-values for comparing each pair of classes. For each class, we selected those G genes that had at least twofold higher expression than in the other two classes, and for which the larger of the two P-values for comparing this group to the other two groups was smallest. We classified the left out sample by majority voting among the five nearest neighboring samples (also on logtransformed data) for the 3 Â G genes selected. Note that redundancy in the probe-sets representing the same Unigene cluster was first eliminated, since otherwise some genes were selected repeatedly. The classifier based on all 40 PCs with known mutations was used to classify the remaining PCs without detected mutations, and it was occasionally necessary to break ties in the majority voting by selecting one of the tied groups that had the closest single sample.
Thyroid tissue arrays and IHC
Two thyroid tissue arrays with a total of 106 PC samples were used in this study and consisted exclusively of tissues from the University of Michigan. Thyroid TMA #2 contained 72 cases of primary PC, and Thyroid TMA #3 contained 34 cases of metastatic PC, with eight cases represented on both arrays. Together, they represented 98 unique PC tumors. The majority of the PCs in these arrays were independent of the PCs used to generate the transcriptional gene expression data set. Six of the PCs present on the tissue arrays were also used in the DNA microarray analysis. Thus, 92 of the 98 unique PCs contained in these two thyroid tissue arrays constituted an independent set. As described above, BRAF mutational analysis using DNA from paraffin blocks was attempted in all 106 PC samples, and results were obtained in 102 samples. BRAF mutations were detected in 54/102 (53%) of the PCs represented in the tissue arrays. IHC for TPO was performed using a mouse monoclonal antibody (clone MoAb47, DakoCytomation, Carpinteria, CA, USA) at a 1 : 200 dilution following microwave antigen retrieval in citrate buffer for 20 min. After incubation for 60 min at room temperature, primary anti-TPO antibodies were detected using the LSAB þ kit (DakoCytomation, Carpinteria, CA, USA).
The TPO-stained thyroid tissue arrays were evaluated by light microscopy using a semiquantitative approach as follows: no staining, 0; faint staining, 1 þ ; moderate staining, 2 þ ; and strong staining, 3 þ . Representative examples of TPO IHC scoring are shown in Figure 4 .
